|
TCMBANKIN005990 |
L-Phenylalanine |
|
C9H11NO2 |
165.19 g/mol |
C1=CC=C(C=C1)CC(C(=O)O)N |
|
TCMBANKIN019832 |
Cysteine |
|
C3H7NO2S |
121.16 g/mol |
C(C(C(=O)[O-])[NH3+])S |
|
TCMBANKIN057923 |
glycin |
Tocris-0219; G5417_SIGMA; WLN: Z1VQ; LS-218; 56-40-6; Glycosthene; G7126_SIGMA; Hgly; Glycine-UL-14C hydrochloride; EINECS 200-272-2; Padil; Polyglycine II; AB-131/40217813; Acido aminoacetico [INN-Spanish]; Glycine [INN]; G7403_SIGMA; CCRIS 5915; GLY (IUPAC abbrev); W328707_ALDRICH; Glycine-2-3H; G3649_SIGMA; InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5; Glycine iron sulphate (1:1); NSC 25936; P8791_SIGMA; Leimzucker; Gyn-Hydralin; D00011; Aminoessigsaeure; 50046_FLUKA; Acidum aminoaceticum [INN-Latin]; Aminoethanoic acid; aminoacetic acid; AI3-04085; 33242-26-1; H2N-CH2-COOH; C00037; G8898_SIGMA; Glyzin; G0398_SIGMA; Amitone; Hampshire glycine; Glycocoll; G5523_SIGMA; Acide aminoacetique [INN-French]; Glycine-carboxy-14C hydrochloride; Glicina [INN-Spanish]; Glycinum [INN-Latin]; Glykokoll; ST5213923; 15527_RIEDEL; 7490-95-1; NChemBio.2007.13-comp1; Glycine, non-medical; BPBio1_001222; Biomol-NT_000195; 57678-19-0; Glycolixir; 63183-41-5; 87867-94-5; HSDB 495; AIDS071643; FEMA No. 3287; CHEBI:15428; 33226_RIEDEL; Sucre de gelatine; 17829-66-2; 410225_SIAL; NCGC00024503-01; 2-Aminoacetic acid; Aminoazijnzuur; NSC25936; Glycine (JP15/USP); polyglycine; 52955-63-2; carbonocyanidic acid; 32817-15-5; 2-aminoethanoic acid; Aciport; L-Glycine; Glicoamin; 25718-94-9; Acetic acid, amino-; G8790_SIGMA; AIDS-071643; NCGC00024503-02; Glycine, homopolymer (VAN); glycine;CHEMBL451140; N'-[N-(2a,3b-Dihydroxy-12-oleanen-28-oyl)-L-alanyl]-glycine; 2-[[(2S)-2-[[(4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]amino]propanoyl]amino]acetic acid;GLY |
C2H5NO2 |
75.07 g/mol |
C(C(=O)O)N |
|
TCMBANKIN057929 |
serine |
(s)-serine;H-Ser; Serinum [Latin]; 56-45-1; SCHEMBL1775; L-Serine, Vetec(TM) reagent grade, >=99%; bmse000867; (2S)-2-amino-3-hydroxypropanoic acid; Serine (L-Serine); EC 200-274-3; 6898-95-9; CS-W020136; L-Serine, homopolymer; CHEBI:17115; H-Ser-OH; S0035; L-Serine, PharmaGrade, Ajinomoto, EP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture; 2-Amino-3-hydroxypropanoic acid-, (S)-; b-Hydroxy-L-alanine; Propanoic acid, 2-amino-3-hydroxy-, (S); L-2-Amino-3-hydroxypropanoic Acid; BRN 1721404; EBD2198140; BC676679; Serinum; Serine (VAN); L-Serine;; NSC760115; (S)-(-)-Serine; AJ-24136; L-3-Hydroxy-2-aminopropionic acid; UNII-00PAR1C66F component MTCFGRXMJLQNBG-REOHCLBHSA-N; EINECS 200-274-3; TC-066532; L-Serine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%; ZINC895034; TL806218; (L)-SERINE; 61748-67-2; L-Serine, Vetec(TM), 98.5%; L-Serine, PharmaGrade, Ajinomoto, EP, USP, JP, Manufactured under appropriate controls for use in pharma or biopharmaceutical production, suitable for cell culture; NCGC00015952-01; Serine (USP); beta-Hydroxyalanine; L-Serine, BioUltra, >=99.5% (NT); Racemic serine; L-Serin; (S)-beta-Amino-3-hydroxypropionate; L-(-)-Serine; NSC 118365; Pharmakon1600-01301010; BR-73019; AK-73019; AmbotzHAA1129; (-)-Serine; (S)-alpha-Amino-beta-hydroxypropionic acid; (2S)-2-amino-3-hydroxy-propanoic acid; CTK1G9788; GTPL726; 452VLY9402; DB00133; 88848-EP2289892A1; MFCD00064224; l-2-Amino-3-hydroxy-propanoic acid; (S)-(+)-2-Amino-3-hydroxypropionic acid; Tocris-0226; (2S)-2-AMINO-2-CARBOXY-1-HYDROXYETHYL; AKOS015854115; 154605-73-9; bmse000048; alpha-Amino-beta-hydroxypropionic acid; bmse000809; MolPort-003-939-270; ser; LS-144975; 88848-EP2305825A1; (S)-a-Amino-b-hydroxypropionic acid; serine; RP09655; DB-029983; RP18847; AC1L1LHF; L-Serine (JP17); L-Serine, Pharmaceutical Secondary Standard; Certified Reference Material; AC-1190; .beta.-Hydroxyalanine; KSC269O8R; KB-53386; BDBM50357212; RTC-066532; NCGC00024507-02; NSC-760115; Lopac-S-4250; D00016; Serina; Propanoic acid, 2-amino-3-hydroxy-, (S)-; NCGC00024507-01; (S)-2-Amino-3-hydroxypropanoic acid; Polyserine; L-Serine, United States Pharmacopeia (USP) Reference Standard; MCULE-5604658333; AM20100375; (S)-Serine; SC-09827; Tocris-0227; L-2-Amino-3-hydroxypropionic acid; bmse000885; AB1002443; UNII-452VLY9402; beta-Hydroxy-L-alanine; 064S224; Serina [Spanish]; L-Serine, Cell Culture Reagent; HSDB 680; Serine, L-; FT-0693445; Serine, European Pharmacopoeia (EP) Reference Standard; L-serine; 3h-l-serine; C00065; (S)-alpha-Amino-beta-hydroxypropionate; L-Serine, certified reference material, TraceCERT(R); Serine [USAN:INN]; 25821-52-7; .alpha.-Amino-.beta.-hydroxypropionic acid-, (S)-; 2-Amino-3-hydroxypropanoic acid, (S)-; F1905-7047; (S)-2-amino-3-hydroxy-Propanoate; (S)-beta-Amino-3-hydroxypropionic acid; L-Serine, ReagentPlus(R), >=99% (HPLC); (S)-2-Amino-3-hydroxypropionic acid; L-Serine, >=99.0% (NT); SR-01000597708; (S)-2-Amino-3-hydroxypropanoate; AN-24441; ST2408299; BP-13282; (S)-2-amino-3-hydroxy-Propanoic acid; CHEMBL11298; 3-hydroxy-L-Alanine; MTCFGRXMJLQNBG-REOHCLBHSA-N; L-Serine, tested according to Ph.Eur.; D0T6GM; PubChem10994; VC30786; Epitope ID:150900; L-3-Hydroxy-2-aminopropionate; L-3-Hydroxy-alanine; M-6047; FT-0627627; Z1270387256; SR-01000597708-1; 3AB40D3A-043A-488F-8361-D1BF309F842C; 4-04-00-03118 (Beilstein Handbook Reference); AB0008559; (S)-a-Amino-b-hydroxypropionate; SER (IUPAC abbrev); L-Alanine, 3-hydroxy-; L-ser; ACT08366; (S)-b-Amino-3-hydroxypropionate; (S)-b-Amino-3-hydroxypropionic acid; 2-Amino-3-hydroxypropionic acid; Poly-L-serine; ANW-32514; rac-serine;(S)-2-Amino-3-hydroxypropionic acid; 2-Amino-3-hydroxypropanoic acid; Serinum [Latin]; S4311_SIGMA; NCGC00024507-02; NSC 118365; Lopac-S-4250; D00016; (2S)-2-amino-3-hydroxypropanoic acid; (-)-Serine; (2S)-2-amino-3-hydroxy-propionic acid; Propanoic acid, 2-amino-3-hydroxy-, (S)-; (S)-alpha-Amino-beta-hydroxypropionic acid; 6898-95-9; (2S)-2-amino-3-hydroxy-propanoic acid; NCGC00024507-01; L-Serine, homopolymer; CHEBI:17115; (S)-2-Amino-3-hydroxypropanoic acid; Polyserine; Propanoic acid, 2-amino-3-hydroxy-, (S); L-3-Hydroxy-alanine; Tocris-0226; (S)-Serine; Tocris-0227; BRN 1721404; L-2-Amino-3-hydroxypropionic acid; beta-Hydroxy-L-alanine; Serina [Spanish]; Serine (VAN); 84959_FLUKA; alpha-Amino-beta-hydroxypropionic acid; HSDB 680; Serine, L-; C00065; 4-04-00-03118 (Beilstein Handbook Reference); L-3-Hydroxy-2-aminopropionic acid; EINECS 200-274-3; L-Serine (JAN); SER (IUPAC abbrev); Serine [USAN:INN]; 25821-52-7; 78682_FLUKA; 2-Amino-3-hydroxypropanoic acid, (S)-; L-Alanine, 3-hydroxy-; S1315_SIGMA; NCGC00015952-01; Serine (USP); Poly-L-serine; beta-Hydroxyalanine; S4500_SIGMA;L-Serin |
C3H7NO3 |
105.09 g/mol |
C(C(C(=O)O)N)O |
|
TCMBANKIN057965 |
arginine |
L(+ )-arginine;EINECS 230-571-3; (2S)-2-amino-5-guanidino-pentanoic acid; EINECS 200-811-1; (S)-2-Amino-5-guanidinovaleric acid; DL-Arginine; (L)-Arginine; Arginine hydrochloride(USAN); 1-Amino-4-guanidovaleric acid; L-Ornithine, N5-(aminoiminomethyl)-; W381918_ALDRICH; (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid; Arginine [USAN:INN]; S-(+)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid; L-Arginine, labeled with tritium; AI3-24165; AIDS-121865; (S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid; NSC203450 (HYDROCHLORIDE); A5006_SIAL; (+-)-Arginine; L-Norvaline, 5-((aminoiminomethyl)amino)-; AIDS121865; Lopac0_000077; Tocris-0663; Arginine (VAN); 4455-52-1; CCRIS 3609; BRN 1725413; NCGC00015064-01; (2S)-2-amino-5-(carbamimidamido)pentanoic acid; (2S)-2-amino-5-guanidinopentanoic acid; D02982; Argininum [INN-Latin]; C00062; 7200-25-1; A8094_SIGMA; 11009_FLUKA; Poly(L-arginine); (2S)-2-amino-5-guanidino-valeric acid; Lopac-A-5006; NSC 206269; HSDB 1429; CHEBI:16467; L-Arginine, homopolymer; L-Arginine (9CI); Arginina [INN-Spanish]; 4-04-00-02648 (Beilstein Handbook Reference); (S)-2-amino-5-guanidinopentanoic acid; (S)-2-Amino-5-((aminoiminomethyl)amino)pentanoic acid; Arginine, L- (8CI); L-Arginine (JP15); EU-0100077; L-alpha-Amino-delta-guanidinovaleric acid; NSC7914 (HYDROCHLORIDE); Arginine (USP); 1119-34-2 (HYDROCHLORIDE); Pentanoic acid, 2-amino-5-((aminoiminomethyl)amino)-, (S)-; L-Arg; L-Norvaline, 5-[(aminoiminomethyl)amino]-; 142-49-4; A4474_SIAL; InChI=1/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s; L-Arginin; Arginine, DL-; NCGC00024715-01;AC1ODX8E; [(4S)-5-amino-4-azaniumyl-5-oxopentyl]-(diaminomethylidene)azanium; [AMINO({[(4S)-4-AMMONIO-4-CARBAMOYLBUTYL]AMINO})METHYLIDENE]AZANIUM |
C6H14N4O2 |
174.2 g/mol |
C(CC(C(=O)O)N)CN=C(N)N |
|
TCMBANKIN057975 |
lysine acid |
|
C6H14N2O2 |
146.19 g/mol |
C(CCN)CC(C(=O)O)N |
|
TCMBANKIN058205 |
trans-resveratrol |
(E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene |
C14H12O3 |
228.24 g/mol |
C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O |
|
TCMBANKIN058241 |
tyrosin;DTY |
Benzenepropanoic acid, alpha-amino-4-hydroxy-, (S)-; HSDB 2003; AIDS192306; L-Phenylalanine-4-hydroxy-; EINECS 200-460-4; 4-Hydroxy-L-phenylalanine; Tyrosine (VAN); alpha-Amino-4-hydroxybenzenepropanoic acid, (S)-; AI3-09055; beta-(p-Hydroxyphenyl)alanine; nchembio816-comp11; AIDS192301; AIDS192308; (S)-2-Amino-3-(p-hydroxyphenyl)propionic acid; CHEBI:17895; AIDS-192301; TYR NH3+ COOH; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours; (S)-2-Amino-3-(4-hydroxyphenyl)propionic acid; Tyrosinum [Latin]; (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid; AIDS-192307; 25619-78-7; L-Tyrosine (9CI); 1991-85-1; L-Tyrosine, homopolymer; AIDS018692; (S)-alpha-Amino-4-hydroxybenzenepropanoic acid; L-Tyrosin; 55520-40-6; Tirosina [Spanish]; (-)-alpha-Amino-p-hydroxyhydrocinnamic acid; alpha-Amino-beta-(4-hydroxyphenyl)propionic acid; BB_NC-1194; D00022; C00082; Tyrosine, L- (8CI); Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction; Tyrosine [USAN:INN]; T3754_SIAL; 140-43-2; NCGC00159350-03; T8566_SIGMA; AIDS-192305; AIDS-018692; 2-Amino-3-(4-hydroxyphenyl)propanoic acid, (S)-; AIDS-192308; AIDS-192306; 2-Amino-3-(4-hydroxyphenyl)propanoic acid-(S)-; 93829_FLUKA; alpha-Amino-p-hydroxyhydrocinnamic acid, (-)-; (S)-Tyrosine; T4321_SIAL; L-Tyrosine, monomer; L-Tyrosine (JAN); Propanoic acid, 2-amino-3-(4-hydroxyphenyl)-(S)-; NCGC00159350-02; AIDS192305; W373605_ALDRICH; 46209-14-7; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide; Tyrosine (USP/INN); FEMA No. 3736; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs; NSC 82624; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide; AIDS192307; (S)-3-(p-Hydroxyphenyl)alanine |
C9H11NO3 |
181.19 g/mol |
C1=CC(=CC=C1CC(C(=O)O)N)O |
|
TCMBANKIN058375 |
tryptophan |
(3s)2,3-dihydro-l-tryptophan; ZINC32141959;tryptophane;WV;L-tryptophan;HSDB 4142; Tryptophan, L-(8CI); AC1Q4U80; L-Tryptophan, Vetec(TM) reagent grade, >=98%; alpha-Aminoindole-3-propionic acid; SR-01000075590-1; ZINC83315; 1-beta-3-Indolylalanine; L-(-)-Tryptophane; MolPort-044-812-611; IDI1_000457; MFCD00064340; L-2-Amino-3-indolepropionic acid; 8DUH1N11BX; STR02722; NCGC00261868-01; EU-0101183; Lopac0_001183; Tryptophan, L-; 80206-30-0; Tryptophan, European Pharmacopoeia (EP) Reference Standard; (s)-a-amino-b-indolepropionate; Tox21_201246; L-Trytophan; bmse000868; TC-066620; (S)-2-amino-3-(1H-Indol-3-yl)-propionic acid; Sedanoct; UNII-8DUH1N11BX; L-Tryptophan, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 99.0-101.0%; Propionic acid, 2-amino-3-indol-3-yl; Propionic acid, 2-amino-3-indol-3-yl-; NINDS_000457; NCI-C01729; (S)-alpha-Aminoindole-3-propionate; L-Tryptophan, Cell Culture Reagent; (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid; bmse001017; AB1007074; tryptophan; BB_NC-1911; 2-amino-3-indol-3-ylpropionic acid; 154635-35-5; Pacitron; L-tryptophan; 2-Amino-3-indolylpropanoate; CTK2H7431; NCGC00094437-01; 2-Amino-3-indolylpropanoic acid; TRP NH3+ COOH; ZX-AT022248; L-Tryptophan, United States Pharmacopeia (USP) Reference Standard; (S)-2-Amino-3-(3-indolyl)propionic acid; Indole-3-alanine; HMS3263N07; L-TRYPTOPHAN SIGMA GRADE; alpha-Amino-3-Indoleproprionic Acid; Tryptophan (USP/INN); L-Tryptophan (9CI); D05EJG; A7403; (L)-TRYPTOPHAN; KSC377I3D; 1H-Indole-3-alanine; Alanine, 3-indol-3-yl-; NCGC00254424-01; MCULE-8004234494; (S)-1H-Indole-3-alanine; AKOS015854052; CHEBI:16828; LP01183; Lopac-T-0254; CHEMBL54976; GTPL717; 3-Indol-3-ylalanine; F0001-2364;HSDB 4142; MT1; T0254_SIAL; tryptophan (H-3); 1-beta-3-Indolylalanine; NChemBio.2007.20-comp7; IDI1_000457; EU-0101183; Lopac0_001183; 80206-30-0; (2S)-2-amino-3-(1H-indol-3-yl)propionic acid; Sedanoct; Propionic acid, 2-amino-3-indol-3-yl-; NINDS_000457; BB_NC-1911; Pacitron; 2-Amino-3-indolylpropanoic acid; (S)-2-Amino-3-(3-indolyl)propionic acid; Indole-3-alanine; (S)-alpha-Amino-beta-(3-indolyl)-propionic acid; Tryptophan (USP/INN); L-Tryptophan (9CI); (L)-TRYPTOPHAN; Alanine, 3-indol-3-yl-; AIDS011920; CHEBI:16828; AIDS-011920; Lopac-T-0254; 3-Indol-3-ylalanine; C00078; Tryptan; TRP-01; (S)-Tryptophan 1H-Indole-3-alanine, (S)-; (S)-Tryptophan; 1H-Indole-3-alanine (VAN); AI3-18478; LS-185087; L-alpha-Aminoindole-3-propionic acid; SMR000326686; L-Alanine, 3-(1H-indol-3-yl)-; L-Trp; L-alpha-Amino-3-indolepropionic acid; Tryptophane; 1H-Indole-3-propanoic acid, alpha-amino-, (S)-; (S)-alpha-Amino-1H-indole-3-propanoic acid; alpha-Amino-3-indolepropionic acid, L-; L-Tryptofan; 1H-Indole-3-alanine, (S)-; 1beta-3-Indolylalanine; (-)-Tryptophan; MLS001056750; alpha'-Amino-3-indolepropionic acid; Indoe-3-propionic acid, alpha-amino-; LTR; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; Indole-3-propionic acid, alpha-amino-; (S)-alpha-Aminoindole-3-propionic acid; Alanine, 3-indol-3-yl; T8941_SIGMA; (S)-alpha-Amino-beta-indolepropionic acid; NSC 13119; CCRIS 617; L-Tryptophane; Tryptophane [French]; Tryptophanum [Latin]; 93659_FLUKA; D00020; Ardeytropin; DivK1c_000457; EINECS 200-795-6; EH 121; Tryptophan, L- (8CI); Triptofano [Spanish]; L-beta-3-Indolylalanine; KBio1_000457; L-(-)-tryptophan; Kalma; NCGC00015994-01; Lyphan; Tryptophan (VAN); h-Trp-oh; Tryptophan [USAN:INN]; L-Tryptophan (JP15); T4196_SIAL Pharmakon1600-01500600; triptofano; UNII-N7U7BXP2OI component QIVBCDIJIAJPQS-VIFPVBQESA-N; 2-Amino-3-(lH-indol-3-yl)-propanoic acid; DTXSID5021419; L-Ttp; Tryptophanum; AM82273; C00078; Tryptan; TRP-01; AJ-10635; L-Tryptophan, BioUltra, >=99.5% (NT); KB-53414; (S)-Tryptophan 1H-Indole-3-alanine, (S)-; (S)-Tryptophan; (S)-a-Aminoindole-3-propionic acid; 2a4m; L-Tryptophan, reagent grade, >=98% (HPLC); 1H-Indole-3-alanine (VAN); AI3-18478; trytophan; LS-185087; BIT0720; CS-W020011; L-alpha-Aminoindole-3-propionic acid; AC1L1M8F; QIVBCDIJIAJPQS-VIFPVBQESA-N; SMR000326686; D-Trp-OH; Tryptophan (L-Tryptophan); L-Alanine, 3-(1H-indol-3-yl)-; CAS-73-22-3; Tox21_501183; L-Trp; OR28930; T 0254; ST2419449; alpha-Amino-beta-(3-indolyl)-propionic acid; UNII-X9U7434L7A component QIVBCDIJIAJPQS-VIFPVBQESA-N; ZX-AFC000605; DSSTox_GSID_21419; Tryptophane; 73T223; 1H-Indole-3-propanoic acid, alpha-amino-, (S)-; (S)-alpha-Amino-1H-indole-3-propanoic acid; alpha-Amino-3-indolepropionic acid, L-; Epitope ID:136043; AX8034769; DSSTox_CID_1419; L-Tryptofan; S(-)-1-alpha-Aminoindole-3-propionic acid; 1H-Indole-3-alanine, (S)-; 1beta-3-Indolylalanine; PubChem10984; (-)-Tryptophan; BDBM21974; MLS001056750; (s)-alpha-amino-beta-indolepropionate; CCG-205257; alpha'-Amino-3-indolepropionic acid; NCGC00094437-02; Indoe-3-propionic acid, alpha-amino-; NSC757373; C-48302; (S)-a-Amino-b-indolepropionic acid; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; Indole-3-propionic acid, alpha-amino-; (S)-alpha-Aminoindole-3-propionic acid; L(-)-Tryptophan; DSSTox_RID_76152; DB-029986; SR-01000075590; BP-13286; l-b-3-Indolylalanine; Alanine, 3-indol-3-yl; (S)-(-)-2-Amino-3-(3-indolyl)propionic Acid; ACT08662; DB00150; NCGC00258798-01; LS-1622; (S)-a-Amino-1H-indole-3-propanoic acid; (S)-alpha-Amino-beta-indolepropionic acid; NCGC00094437-04; BR-50074; AB00373874_05; RTC-066620; bmse000050; NSC 13119; L-Tryptophan, PharmaGrade, Ajinomoto, EP, JP, USP, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture; alpha-amino-beta-(3-indolyl)-pr opionic acid; GM0674; CCRIS 617; L-Tryptophane; Tryptophanum [Latin]; Tryptophane [French]; L-Tryptophan, certified reference material, TraceCERT(R); Tryptophan (H-3); (S)-a-Amino-1H-indole-3-propanoate; Tox21_300359; trp; AK-50074; Alti-Tryptophan; ANW-36308; Ardeytropin; D00020; DivK1c_000457; L-Tryptophan (JP17); (S)-(-)-Tryptopha n; NCGC00094437-03; L-Trp-OH; EINECS 200-795-6; (S)-2-Amino-3-(3-indolyl)propionic acid; L-; EH 121; EC 200-795-6; Optimax; L-Trytophane; HMS501G19; Tryptophan, L- (8CI); NSC-757373; M02943; (S)-(-)-Tryptophan; HTS001390; RP26086; Triptofano [Spanish]; (S)-alpha-amino-beta-(3-indolyl)-propionic acid; L-beta-3-Indolylalanine; A-Amino-3-indolepropionic acid; 151A3008-4CFE-40C9-AC0B-467EF0CB50EA; MolPort-001-794-499; KBio1_000457; BG00603884; 73-22-3; Kalma; NCGC00015994-01; AN-8742; 3-(1H-indol-3-yl)-L-Alanine; FT-0627592; Lyphan; Tryptophan (VAN); trofan; L-Tryptophan premix; L-Tryptophan, Vetec(TM), 98.5%; AC-17050; L-alpha-amino-3-indolepropionic acid; h-Trp-oh; 1qaw; SCHEMBL7328; Tryptophan [USAN:INN]; L-(-)-Tryptophan; L-Tryptophan (JP15); phosphatidylserine; (S)-alpha-Amino-1H-indole-3-propanoate; l-a-Aminoindole-3-propionic acid; D-2-Amino-3-indolepropionic acid; Z1245635763; (S)-a-Aminoindole-3-propionate; tryptacin |
C11H12N2O2;C3H8NO6P |
204.22 g/mol;185.07g/mol |
C1=CC=C2C(=C1)C(=CN2)CC(C(=O)O)N |
|
TCMBANKIN059452 |
ethyl aldehyde |
|
C2H4O |
44.05 g/mol |
CC=O |
|
TCMBANKIN059684 |
Vitamin E β- |
|
C29H50O2 |
430.79 |
CC1=C(C(=C2CCC(OC2=C1C)(C)CCCC(C)CCCC(C)CCCC(C)C)C)O |
|
TCMBANKIN059746 |
α-tocopherol |
|
C29H50O2 |
430.7 g/mol |
CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C |
|
TCMBANKIN059815 |
tanshinone i |
|
C18H12O3 |
276.3 g/mol |
CC1=C2C=CC3=C(C2=CC=C1)C(=O)C(=O)C4=C3OC=C4C |
滇IICP备16009434号-1 |
Dai SX Lab